Danielle Brill
Stock Analyst at Truist Securities
(3.75)
# 714
Out of 5,147 analysts
100
Total ratings
44.44%
Success rate
10.75%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine | Maintains: Buy | $114 → $83 | $66.62 | +24.59% | 8 | Feb 27, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $86 → $95 | $66.48 | +42.90% | 4 | Feb 25, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $169 → $140 | $132.25 | +5.86% | 9 | Feb 17, 2026 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $33 → $38 | $26.86 | +41.47% | 3 | Jan 29, 2026 | |
| TECX Tectonic Therapeutic | Maintains: Buy | $64 → $60 | $23.45 | +155.86% | 3 | Jan 8, 2026 | |
| IMVT Immunovant | Maintains: Hold | $16 → $22 | $27.73 | -20.66% | 6 | Jan 8, 2026 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $48 → $45 | $28.54 | +57.67% | 9 | Jan 8, 2026 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $56 → $63 | $55.19 | +14.15% | 2 | Jan 8, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $535 → $530 | $332.92 | +59.20% | 3 | Jan 8, 2026 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $105 → $190 | $135.02 | +40.72% | 4 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $7.68 | +511.98% | 1 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $496.83 | - | 3 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $20.63 | +16.34% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $20 → $52 | $15.63 | +232.69% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $21.18 | - | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $79 | $61.73 | +27.98% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $18 | $9.04 | +99.12% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $150 | $16.76 | +794.99% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $191.82 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $766.92 | -21.11% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $24.56 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $43.23 | +15.66% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $30.23 | +68.71% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $100 | $9.12 | +996.49% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $68.19 | - | 9 | Sep 18, 2023 |
Disc Medicine
Feb 27, 2026
Maintains: Buy
Price Target: $114 → $83
Current: $66.62
Upside: +24.59%
BridgeBio Pharma
Feb 25, 2026
Maintains: Buy
Price Target: $86 → $95
Current: $66.48
Upside: +42.90%
Neurocrine Biosciences
Feb 17, 2026
Maintains: Buy
Price Target: $169 → $140
Current: $132.25
Upside: +5.86%
Centessa Pharmaceuticals
Jan 29, 2026
Maintains: Buy
Price Target: $33 → $38
Current: $26.86
Upside: +41.47%
Tectonic Therapeutic
Jan 8, 2026
Maintains: Buy
Price Target: $64 → $60
Current: $23.45
Upside: +155.86%
Immunovant
Jan 8, 2026
Maintains: Hold
Price Target: $16 → $22
Current: $27.73
Upside: -20.66%
Harmony Biosciences Holdings
Jan 8, 2026
Maintains: Buy
Price Target: $48 → $45
Current: $28.54
Upside: +57.67%
Dianthus Therapeutics
Jan 8, 2026
Maintains: Buy
Price Target: $56 → $63
Current: $55.19
Upside: +14.15%
Alnylam Pharmaceuticals
Jan 8, 2026
Maintains: Buy
Price Target: $535 → $530
Current: $332.92
Upside: +59.20%
Palvella Therapeutics
Dec 16, 2025
Maintains: Buy
Price Target: $105 → $190
Current: $135.02
Upside: +40.72%
Oct 14, 2025
Initiates: Buy
Price Target: $47
Current: $7.68
Upside: +511.98%
Sep 3, 2025
Initiates: Market Perform
Price Target: n/a
Current: $496.83
Upside: -
Jul 21, 2025
Initiates: Buy
Price Target: $24
Current: $20.63
Upside: +16.34%
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $15.63
Upside: +232.69%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $21.18
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $61.73
Upside: +27.98%
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $9.04
Upside: +99.12%
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $16.76
Upside: +794.99%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $191.82
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $766.92
Upside: -21.11%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $24.56
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $43.23
Upside: +15.66%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $30.23
Upside: +68.71%
Nov 14, 2023
Maintains: Outperform
Price Target: $180 → $100
Current: $9.12
Upside: +996.49%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $68.19
Upside: -